Depending on our advanced techniques and years of experiences, Creative Biolabs has been well known worldwide for its superb CellRapeutics™ Chimeric Antigen Receptor (CAR) products targeting Lymphoma-specific antigens. Our seasoned scientists can offer you the best service and a full range of befitting strategies to promote your research progress.
Michael H. Kershaw, Michele W. L. Teng, Mark J. Smyth & Phillip K. Darcy.
Supernatural T cells: genetic modification of T cells for cancer therapy. Nature Reviews Immunology 5, 928-940 (December 2005)
Lymphoma is a class of cancer which affects the lymph system. The two main types of lymphoma are described as Hodgkin lymphoma (HL) and non Hodgkin lymphoma (NHL) respectively, the common symptoms of which include: pain or painless swelling of lymph nodes, fever, weight loss, sweating especially at night, chills, weakness and itching. The exact etiology of lymphoma is not well known, however, certain factors may increase the risk of this disease such as overexposure to chemicals or radiation, virus infection, DNA mutation or translocations, inherited immune deficiencies and immune system disorders. Chemotherapy, radiation therapy, biologic therapy or a combination of these therapies are often used in the treatment of lymphoma. But, these traditional approaches always have long-term side effects. In the last decade, CAR-T cell therapy has become a promising field for lymphoma treatment, which can overcome certain drawbacks. With the most advanced techniques, our experienced scientists can provide highly customized service for CARs production which can greatly promote your research progress.
Based on targeting different Lymphoma antigens, we can provide a variety of world leading CARs production service as listed in the table below. Meanwhile, Creative Biolabs is pleased to announce that we can also offer bespoke service to meet various requirements from our customers. Please feel free to contact us.
Products against Lymphoma-specific antigens
|Associated malignancy||Target antigen||Receptor type||Product|
|Hodgkin lymphoma (HL)||CD30||scFv-CD3ζ||CAR-MZ061|
|Mature T cell and natural killer (NK) cell neoplasms||TAX||TCR-L130|
|Precursor lymphoid neoplasms||DLBCL||TCR-C039Z|
|Non-Hodgkin lymphomas||Kappa light chain||scFv-41BB-CD3ζ||CAR-LC217|
For any technical issues or products/services related questions, please leave your information below. Our team will contact you soon.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
Angiotensin-converting Enzyme 2 (ACE2)-CHO Cell Line Model for COVID-19: Helps researchers to further study the interaction between the receptor ACE2 and the COVID-19 virus.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE